Kolexia
Ammarguellat Hanifa Radio-thérapie
Ammarguellat Hanifa
Radio-thérapie
Centre Hospitalier de Beauvais
Beauvais, France
50 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du côlon Récidive tumorale locale Adénocarcinome Carcinome épidermoïde Carcinomes Tumeurs de l'oesophage Carcinome épidermoïde de la tête et du cou Insuffisance surrénale Tumeurs du système nerveux central

Collaborateurs

Voir plus
Hocine Faycal
Hocine Faycal
Centre De Traitements Hautes Energies, Amiens, France
Ramdane Soraya
Ramdane Soraya
Centre Hospitalier de Beauvais, Beauvais, France
Coutte Alexandre
Coutte Alexandre
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France
Bresson-Raynaud Isabelle
Bresson-Raynaud Isabelle
Centre Hospitalier de Beauvais, Beauvais, France

Industries

Voir plus
B3TSI
14 collaboration(s)
Dernière en 2023
AstraZeneca
6 collaboration(s)
Dernière en 2023
Ipsen
4 collaboration(s)
Dernière en 2023
PASCALEO
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
LOGICAN: Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Essai Clinique (Servier)   12 octobre 2023
Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers.
Acta oncologica (Stockholm, Sweden)   20 juin 2023
Rechute tumorale atypique révélée par une insuffisance surrénalienne et corticotrope
85e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 décembre 2022
A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.
2022 ASCO Annual Meeting I   02 juin 2022
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland   10 mars 2021
OPTINECK: Evaluation of Optimised Early Management in the Context of Radiochemotherapy for Curatively Treated Squamous Cell Carcinoma of the Head and Neck
Essai Clinique (Centre Henri-Becquerel)   26 août 2020
Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).
Annals of surgery   04 juin 2020
Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial.
2020 ASCO Annual Meeting I   25 mai 2020
ECKINOXE: PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer
Essai Clinique (Merck-Serono)   14 janvier 2016